CYDX (Cyduct Diagnostics) Total Receivables: $0.00 Mil (As of . 20)


What is Cyduct Diagnostics Total Receivables?

Cyduct Diagnostics CYDX -17.78% Total Receivables is $0.00 Mil as of . 20.

Cyduct Diagnostics's Total Receivables for the quarter that ended in . 20 was $0.00 Mil.

Cyduct Diagnostics Total Receivables Related Terms

Cyduct Diagnostics Total Receivables Historical Data

* Premium members only.

The historical data trend for Cyduct Diagnostics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyduct Diagnostics Total Receivables Chart

Cyduct Diagnostics Annual Data
Trend
Total Receivables

Cyduct Diagnostics Quarterly Data
Total Receivables

Cyduct Diagnostics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.00 Mil mean?
Cyduct Diagnostics (CYDX) has a Total Receivables of $0.00 Mil as of . 20. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Cyduct Diagnostics and its competitors.
Is Cyduct Diagnostics' Total Receivables too high?
Cyduct Diagnostics' current Total Receivables is $0.00 Mil.
How does Cyduct Diagnostics' Total Receivables compare to SECI and QTXB?
Cyduct Diagnostics' Total Receivables of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Devices & Instruments company?
A good Total Receivables depends on the Medical Devices & Instruments industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Cyduct Diagnostics and its competitors. Cyduct Diagnostics's current Total Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyduct Diagnostics stock overvalued right now?
Cyduct Diagnostics (CYDX) has a current Total Receivables of $0.00 Mil. The current Total Receivables is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Cyduct Diagnostics (CYDX), the current Total Receivables is $0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cyduct Diagnostics Business Description

Address 1698 Post Road East, Suite 1A, Westport, CT, USA, 06880
Cyduct Diagnostics Inc is a clinical-stage diagnostic company. It focuses on creating and enhancing a portfolio of technologies and assets based on the early assessment and detection of Breast Cancer. Its technology platform of MammoView devices is a single-use, high-margin product that assesses, screens, detects, monitors, and facilitates the treatment of identifiable changes that distinguish variations in breast health. The company markets these products under its Solos Endoscopy brand, along with a line of branded surgical instruments, manufactured by third parties to its design specifications, mainly endoscopes and hand-held surgical instruments for the minimally invasive surgery market.